Benchmark analyst Mike Hickey lowered his price target on Canadian-traded shares of Canopy Growth to C$30 from C$60 following the company's "disappointing" Q2 performance, stating that he suspects investors are now favoring disciplined growth and a path to profitability given that the global and domestic cannabis market are not achieving the presumed near-term growth opportunity. He anticipates near-term performance trends will improve and keeps a Buy rating on Canopy shares, also citing future catalysts such as the opening of the U.S. CBD market and "Cannabis 2.0."

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here